Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology.
Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article.
Full article available here.